Compagnie Lombard Odier SCmA - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
Compagnie Lombard Odier SCmA ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$18,540
+67.6%
1,0000.0%0.00%
Q2 2023$11,060
-17.6%
1,0000.0%0.00%
Q1 2023$13,430
+11.9%
1,0000.0%0.00%
Q4 2022$12,000
-14.3%
1,0000.0%0.00%
Q3 2022$14,0000.0%1,0000.0%0.00%
Q2 2022$14,000
-12.5%
1,0000.0%0.00%
Q1 2022$16,0000.0%1,0000.0%0.00%
Q4 2021$16,000
+6.7%
1,0000.0%0.00%
Q3 2021$15,000
-25.0%
1,0000.0%0.00%
Q2 2021$20,000
-13.0%
1,0000.0%0.00%
-100.0%
Q1 2021$23,000
-8.0%
1,0000.0%0.00%0.0%
Q4 2020$25,000
-39.0%
1,0000.0%0.00%0.0%
Q3 2020$41,000
-14.6%
1,0000.0%0.00%
-50.0%
Q2 2020$48,000
-23.8%
1,0000.0%0.00%
-33.3%
Q1 2020$63,000
-49.2%
1,0000.0%0.00%
-40.0%
Q4 2019$124,000
+87.9%
1,0000.0%0.01%
+66.7%
Q3 2019$66,000
-17.5%
1,0000.0%0.00%0.0%
Q2 2019$80,000
-11.1%
1,000
-35.4%
0.00%0.0%
Q3 2017$90,000
-54.8%
1,549
-11.9%
0.00%
-57.1%
Q1 2017$199,000
-42.8%
1,759
-27.8%
0.01%
-30.0%
Q2 2016$348,000
-24.5%
2,436
-32.1%
0.01%
-28.6%
Q1 2016$461,000
+4090.9%
3,587
+8867.5%
0.01%
Q1 2015$11,000
+83.3%
400.0%0.00%
Q4 2014$6,000400.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders